BioNxt Solutions Inc.

Healthcare US BNXTF

0.3456USD
0.00(0%)

Last update at 2026-06-02T20:00:00Z

Day Range

0.330.33

LowHigh

52 Week Range

0.260.80

LowHigh

Fundamentals

Previous Close 0.35
Market Cap47.70M
Volume200
P/E Ratio-
Dividend Yield-%
EBITDA-5.22932M
Revenue TTM0.02M
Revenue Per Share TTM-
Gross Profit TTM 0.02M
Diluted EPS TTM-0.04

Overview
Financials
Peer Comparison
Reports
Stock Research & News
Profile

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Income before tax	-5.40130M	-7.72293M	-12.86998M	-20.74784M	-17.24725M
Minority interest	-	-	-	-	-
Net income	-5.31151M	-7.72293M	-12.37607M	-20.63710M	-16.88976M
Selling general administrative	2.80M	3.52M	3.93M	12.36M	11.01M
Selling and marketing expenses	-	-	-	-	-
Gross profit	-	0.37M	0.20M	0.20M	-
Reconciled depreciation	0.09M	0.20M	0.22M	0.82M	0.90M
Ebit	-	-	-	-16.21396M	-14.70288M
Ebitda	-	-	-11.51182M	-19.19276M	-16.05370M
Depreciation and amortization	-	-	-	-	-
Non operating income net other	-	-	-	-	-
Operating income	-4.56739M	-6.38724M	-6.04493M	-16.31005M	-14.80370M
Other operating expenses	-	-	-	-	-
Interest expense	0.99M	1.04M	1.14M	0.73M	0.30M
Tax provision	-0.08979M	0.00000M	-0.49391M	-0.11074M	-0.35749M
Interest income	0.00030M	0.00000M	-	-	-
Net interest income	-0.98485M	-1.04255M	-1.14256M	-0.73186M	-0.29708M
Extraordinary items	-	-	-	-	-
Non recurring	-	-	-	-	-
Other items	-	-	-	-	-
Income tax expense	-	-	-	-0.11074M	-0.35749M
Total revenue	0.03M	0.37M	0.30M	0.29M	0.35M
Total operating expenses	4.59M	6.76M	6.34M	16.60M	15.15M
Cost of revenue	-	0.00000M	0.10M	0.09M	-
Total other income expense net	0.15M	-0.29314M	-5.68250M	-3.70593M	-2.14648M
Discontinued operations	-	-	-	-	-
Net income from continuing ops	-5.31151M	-7.72293M	-12.37607M	-20.63710M	-16.88976M
Net income applicable to common shares	-	-	-	-20.63710M	-16.88976M
Preferred stock and other adjustments	-	-	-	-	-

Breakdown	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Total assets	0.57M	1.27M	1.61M	9.73M	8.28M
Intangible assets	-	0.00000M	0.00001M	1.02M	0.01M
Earning assets	-	-	-	-	-
Other current assets	-	-	-	-	-
Total liab	8.43M	6.55M	5.74M	8.06M	4.28M
Total stockholder equity	-7.86146M	-5.28266M	-4.12840M	1.67M	4.01M
Deferred long term liab	-	-	-	-	-
Other current liab	0.06M	0.15M	-	-	-
Common stock	-	-	-	39.35M	24.59M
Capital stock	52.61M	50.75M	45.38M	39.35M	24.59M
Retained earnings	-64.68832M	-59.92843M	-55.54680M	-43.37738M	-24.92644M
Other liab	-	-	-	0.28M	-
Good will	-	-	0.00000M	4.87M	0.00000M
Other assets	-	-	-	-	-
Cash	0.03M	0.36M	0.14M	1.35M	2.58M
Cash and equivalents	-	-	-	-	-
Total current liabilities	6.88M	6.55M	2.02M	5.45M	1.47M
Current deferred revenue	-	-	-	-	-
Net debt	4.25M	4.53M	4.20M	3.29M	-
Short term debt	-	-	-	-	-
Short long term debt	2.73M	4.89M	0.61M	2.98M	0.35M
Short long term debt total	-	-	-	-	-
Other stockholder equity	-	-	-	5.90M	4.35M
Property plant equipment	-	-	-	1.13M	5.24M
Total current assets	0.16M	0.72M	0.69M	2.70M	3.03M
Long term investments	-	-	-	-	-
Net tangible assets	-	-	-	-4.22493M	3.99M
Short term investments	-	-	-	-	-
Net receivables	0.06M	0.28M	0.46M	0.55M	0.31M
Long term debt	1.55M	-	3.72M	1.66M	2.02M
Inventory	-	-	0.00000M	0.74M	-
Accounts payable	1.11M	0.60M	0.46M	2.32M	0.57M
Total permanent equity	-	-	-	-	-
Noncontrolling interest in consolidated entity	-	-	-	-	-
Temporary equity redeemable noncontrolling interests	-	-	-	-	-
Accumulated other comprehensive income	-	-	-	-	-
Additional paid in capital	-	-	-	-	-
Common stock total equity	-	-	-	-	-
Preferred stock total equity	-	-	-	-	-
Retained earnings total equity	-	-	-	-	-
Treasury stock	-	-	-	-	-
Accumulated amortization	-	-	-	-	-
Non currrent assets other	-	-	-	-	-
Deferred long term asset charges	-	-	-	-	-
Non current assets total	0.41M	0.55M	0.92M	7.02M	5.25M
Capital lease obligations	-	0.00000M	0.03M	0.82M	0.94M
Long term debt total	-	-	-	-	-

Breakdown	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Investments	0.06M	0.10M	-0.00386M	-5.30796M	-0.15647M
Change to liabilities	-	-	0.00000M	0.46M	0.22M
Total cashflows from investing activities	-	-	-	-5.30796M	-0.15647M
Net borrowings	1.08M	-0.24754M	-	1.87M	4.23M
Total cash from financing activities	2.64M	5.29M	5.02M	16.23M	12.65M
Change to operating activities	-	-	-	0.08M	-0.01296M
Net income	-5.31151M	-7.72293M	-12.37607M	-20.63710M	-16.88976M
Change in cash	-0.33130M	0.23M	-1.21578M	-1.23296M	2.29M
Begin period cash flow	0.36M	0.14M	1.35M	2.58M	0.30M
End period cash flow	0.03M	0.36M	0.14M	1.35M	2.58M
Total cash from operating activities	-3.03412M	-5.16756M	-6.22971M	-12.15505M	-10.20494M
Issuance of capital stock	1.71M	4.43M	6.10M	7.35M	0.00000M
Depreciation	0.09M	0.20M	0.21M	0.82M	0.89M
Other cashflows from investing activities	-	-	-	-	-
Dividends paid	-	-	-	-	-
Change to inventory	-	0.00000M	0.13M	-0.73616M	-0.73616M
Change to account receivables	-	-	-	-0.21452M	-0.17587M
Sale purchase of stock	-	-	-	-	-
Other cashflows from financing activities	-	-	-	-0.58958M	-0.58958M
Change to netincome	-	-	-	8.08M	5.76M
Capital expenditures	0.00000M	0.20M	0.00386M	0.45M	0.16M
Change receivables	-	-	-	-	-
Cash flows other operating	-	-	-	-	-
Exchange rate changes	-	-	-	-	-
Cash and cash equivalents changes	-	-	-	-	-
Change in working capital	0.79M	0.48M	-0.55955M	-0.41873M	0.03M
Stock based compensation	0.55M	0.61M	0.11M	3.28M	2.59M
Other non cash items	1.07M	1.06M	0.45M	1.24M	1.48M
Free cash flow	-3.03412M	-5.36899M	-6.23357M	-12.60740M	-10.36141M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company	Change (USD)	Price (USD)	Trailing PE (x)	Forward PE (x)	Price Sales TTM (x)	Price to Book Value (x)	Enterprise Value to Revenue (x)	Enterprise Value to EBITDA (x)
BNXTF BioNxt Solutions Inc.	- -%	0.35	-	-	3014.99	21.77	3980.66	-4.0223
ZTS Zoetis Inc	1.20 1.57%	77.59	40.18	30.96	10.67	17.60	11.27	26.18
MKKGY Merck KGaA ADR	0.58 1.91%	31.01	21.25	14.93	3.10	2.14	3.60	12.98
MKGAF MERCK Kommanditgesellschaft auf Aktien	- -%	153.91	21.73	14.95	3.16	2.15	3.56	12.82
GALDY GALDERMA GROUP AG	-0.79 1.89%	40.92	74.21	41.67	8.64	5.55	9.15	42.22

Reports Covered

View All

Profile

BioNxt Solutions Inc. engages in research, development, manufacture, and sale of next generation drug formulations and delivery systems in Austria, Germany, and Switzerland. The company provides BNT23001for the treatment of multiple sclerosis; BNT23002 for the treatment of myasthenia gravis; BNT24002, a sublingual thin film for the treatment of lupus nephritis; BNT24003 for the treatment of rheumatoid arthritis; BNT24004 for longevity and anti-aging; and BNT24004 for the treatment of semaglutide. It also offers diagnostic screening tests; new active pharmaceutical production and evaluation, including precision transdermal and oral dissolvable drug formulations; infectious disease and oral health screening tests; and standardization and clinical evaluation of emerging active pharmaceutical ingredients for neurological applications. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. BioNxt Solutions Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.

BioNxt Solutions Inc.

1928 Linden Road, Vancouver, BC, Canada, V6M 1E7

780 818 6422
https://www.bionxt.com

Key Executives

Name	Title	Year Born
Mr. Wolfgang Probst	Co-Founder, Interim CEO & Director	1981
Mr. Hugh A. D. Rogers B.Sc., LL.B	Co-Founder & Director	1980
Dr. Raimar Lobenberg Ph.D.	Co-Founder & Director	1966
Mr. Patrick Joseph Meagher C.A., CPA, CA, CPA	CFO, Corporate Secretary & Director	1986
Dr. Florian A. Sahr	Head of Project Management	NA
Dr. Wolfgang Wagner	Head of Research & Development	NA
Mr. Hugh A. D. Rogers B.Sc., LL.B	Co-Founder, CEO & Director	1980
Mr. Wolfgang Probst	Co-Founder, CFO & Corporate Secretary	1982

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.